-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
February 28 this year is the 14th International Rare Disease Day.
Multiple sclerosis (MS) is a serious, lifelong, progressive, and disabling demyelinating disease of the central nervous system.
According to the course of the disease, MS is divided into four types, namely relapsing-remitting type (RRMS approximately 85%), secondary progressive type (SPMS), primary progressive type (PPMS approximately 10%) and progressive relapsing type (PRMS approximately 5%) ), 80% of RRMS can be developed into SPMS.
According to statistics, currently approved MS drugs mainly include interferon, corticotropin, glatiramer, monoclonal antibodies and oral chemical drugs.
Recently, with the announcement of the company's financial reports, most MS drugs have been released in 2020, as shown in the table below.
The active ingredient ofatumumab of Novartis’ Kesimpta is also a CD20 monoclonal antibody.
In addition, BMS’s Ozamod and Novartis’ Sinimod are two SIPR modifiers approved in the past three years.
Looking at the MS drugs in the TOP100 global drug sales from 2017 to 2019, dimethyl fumarate has been firmly at the top of the MS drug sales rankings, but its sales and rankings have declined in 2020.
In addition, Teva's Glatiramer acetate (Copaxone) sales and rankings have declined significantly.
Teriflunomide (Aubagio) is an oral pyrimidine synthase inhibitor and immunomodulator.
From an enterprise perspective, Bojian is still the first transaction in the MS market.
In addition to the above-mentioned MS drugs, in recent years, with the emphasis on rare diseases at home and abroad, the reform of the approval system, and the efforts of patient organizations, more and more rare disease drugs have been quickly marketed to benefit patients.
Reference materials:
[1] Overview of the global drug market for multiple sclerosis_Bojian
https:// style="vertical-align: inherit;">[2] What are the "firsts" in the rare disease treatments approved in 2020? ｜International Rare Disease Day_Tencent News
https://new.
[3] Financial reports of companies
